View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 1, 2022

Moderna signs contract to supply Covid-19 booster vaccines to the US

The initial 66 million vaccine doses are anticipated to be supplied this year.

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222.

The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

A bivalent booster candidate, the mRNA-1273.222 vaccine comprises Spikevax along with the Omicron BA.4/5 strain messenger RNA (mRNA).

Spikevax is the company’s Covid-19 vaccine intended for active immunisation for disease prevention in people aged 18 years and above.

The initial vaccine doses of 66 million are anticipated to be supplied this year. On the US exercising options, the doses could total 300 million.

Last month, the company announced the advancement of two bivalent candidates based on various population health security approaches in different countries. 

The mRNA-1273.222 vaccine containing the BA.4/5 Omicron strain is being developed in line with the latest recommendations from the Food and Drug Administration (FDA). 

Another vaccine, mRNA-1273.214, comprises the BA.1 Omicron strain, which could be of benefit as observed by the World Health Organization (WHO). 

On obtaining authorisations, these updated bivalent vaccines could potentially provide enhanced, wider and long-lasting protection against Covid-19.

Moderna CEO Stéphane Bancel said: “Moderna’s mRNA platform is enabling us to rapidly create mRNA-1273.222, a bivalent vaccine that specifically targets Omicron subvariants BA.4 and BA.5, the most prevalent variants of concern in the US today. 

“We remain fully committed to leveraging our innovative technology platform to offer tailored vaccines that help protect communities against Covid-19.”

The US Department of Health and Human Services, and Administration for Strategic Preparedness and Response (ASPR) and others are supporting the deal through federal funds.

In June, the company and the European Commission (EC) signed an agreement to amend their previously agreed contractual supply schedules for the former’s Covid-19 vaccine booster product (Spikevax, mRNA-1273) or updated booster vaccine candidate.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology